In May Legal Alliance Company successfully protected in the District Administrative Court of Kyiv interests of one of the leading national pharmaceutical manufacturers in a dispute with the Ministry of Economic Development and Trade of Ukraine on cancellation of an order for a special sanction.
Thus, the Ministry of Economic Development and Trade of Ukraine based on application of the Security Service of Ukraine adopted an order under which a special sanction, individual regime of licensing of foreign economic activities, was imposed for alleged violation of Article 476 of the Customs Code of Ukraine (“Importing the Goods Through the Customs Border of Ukraine Violating Intellectual property Rights”) on a subject of foreign economic activities of Ukraine.
While considering the case, attorneys of Legal Alliance Company collected evidence that there were no violations of Article 476 of the Customs Code of Ukraine by a leading national pharmaceutical manufacturer, and also grounded a legal position in the case in detail.
Consequently, the District Administrative Court of Kyiv satisfied in full the claims and abolished order of the Ministry of Economic Development and Trade of Ukraine on imposition of a special sanction on our client.
Interests of a client in the dispute were represented by Iryna Shlyakhovska, senior associate at Legal Alliance Company.
Contact the author: Iryna Shlyakhovska, senior associate at Legal Alliance Company, shlyahovskaya@l-a.com.ua
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
